Celltrion
http://
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Celltrion
Celltrion Files Subcutaneous Infliximab In US – As Standalone BLA
Celltrion is seeking US approval for its subcutaneous formulation of infliximab, marketed in other territories as Remsima SC. The product will be registered as a standalone biologic rather than a biosimilar.
At The Edge Of The Cliff: Five Blockbuster Drugs Set To Lose US Patent Exclusivity In 2023
With the advent of 2023, comes the start of the industry’s next patent cliff, with five products that reached billions in sales at their peak set to lose US patent exclusivity during the year. Scrip takes a look into how the affected big pharma firms are preparing for anticipated market erosion and which generic and biosimilar companies are positioned to benefit the most.
Keeping Track: Orphans Headline FDA Approvals; Gene Therapies Stand Out Among Submissions
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Asia Deal Watch: Dong-A Brings In NeuroBo As Partner On Pair Of Cardiometabolic Candidates
Plus deals involving Takeda/Puma, SillaJen/Basilea, Celltrion/Abpro, METiS/Voronoi, Yuhan/AtoGen, Biocytogen/FineImmune and Avance/C3.
Company Information
- Industry
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice